Views & Analysis Building honest dialogue with patient advocates How can the industry listen to patients in a way that puts the person behind the disease first?
News Otsuka grows in neuroplastogens with $1.225bn Transcend buy Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
